Biopharmaceutical labs are facing increasing demands and reduced resources, with the focus on efficiency and time optimization crucial for innovation. Tola Olorunnisola, senior vice president and general manager at Avantor, discusses the potential of AI and automation to enable scientific breakthroughs and revolutionize the drug development process. These technologies have become integral in evaluating and optimizing lab workflows, managing inventory, assets, personnel and samples, and improving efficiency for lab managers. The integration of automation and AI is revolutionizing the process of drug development in numerous ways, including streamlining repetitive tasks and reducing potential for human error. Olorunisola also highlights the potential for AI to personalize treatments and increase the efficacy and safety of new therapies.
Source
This post was brought to you by Wrk. Our bot looks for news related to automation and post daily.
